Arlene O. Siefker-Radtke, MD, MD Anderson Cancer Center, Houston, TX, discusses the randomized, open-label Phase III THOR study (NCT03390504) trial which evaluated the efficacy of erdafitinib versus pembrolizumab in pre-treated patients with advanced or metastatic urothelial cancer (UC) who harbored selected fibroblast growth factor receptor alterations (FGFRalt) and were anti-PD-(L)1-naïve. The primary endpoint was not met, with no statistically significant difference in overall survival (OS) between the two treatment arms. The erdafitinib arm exhibited a numerically longer progression-free survival (PFS) and numerically higher objective response rate (ORR), but a shorter duration of response. The most common treatment-related adverse events in the erdafitinib arm included hyperphosphatemia, stomatitis, and diarrhea; and in the pembrolizumab arm, pruritus, asthenia, and hypothyroidism. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
